The Combined Strength of Two Pioneers in The DNA Data Storage and Computing Market is poised to accelerate the emergence of new high-density and energy-efficient Information Systems

两家在DNA数据存储和计算市场上的先驱者的力量结合，将加速新型高密度、高能效信息系统的发展。

PARIS and BOSTON

巴黎和波士顿

,

，

March 5, 2026

2026年3月5日

/PRNewswire/ --

/PRNewswire/ --

Biomemory

生物记忆

, a leader in DNA Data Storage systems tailored for the IT and Cybersecurity industries, today announced the acquisition of the assets from Catalog Technologies, the Boston-based historical pioneer of DNA Data Storage and Computing. Both technologies synergistically align, combining enzymatic bio-secure DNA blocks assembly with scalable high-speed printing, high-throughput reading and a low error-rate - supporting Biomemory's objective to deploy its interoperable solutions at scale in data centers.

，一家为IT和网络安全行业量身打造的DNA数据存储系统的领导者，今天宣布收购总部位于波士顿的DNA数据存储与计算领域的历史性先驱Catalog Technologies的资产。这两项技术具有协同效应，将酶促生物安全DNA模块组装与可扩展的高速打印、高通量读取以及低错误率相结合，助力Biomemory实现其在数据中心大规模部署互操作性解决方案的目标。

The transaction creates a unique and unrivaled combination of technology, expertise, hardware and Intellectual Property under a single roof. Additionally, it increases Biomemory's footprint, establishing an entity in North America with Research & Development, production and customer support for the Data Storage & Computing market.            .

这笔交易将技术、专业知识、硬件和知识产权独特且无与伦比地结合在了一起。此外，它还扩大了Biomemory的业务范围，在北美建立了一个针对数据存储和计算市场的研发、生产和客户支持实体。

Acceleration and Extension of the Portfolio

投资组合的加速与扩展

Beyond technology alignment, the acquisition brings an unmatched set of opportunities to accelerate the delivery of enterprise-grade secure DNA Data Storage and Computing solutions. Capitalizing on its patented method for the volume production of biosafe DNA and enzymatic consumables, Biomemory can ensure a competitive operating cost (OpEx).

除了技术协同之外，此次收购还带来了加速交付企业级安全DNA数据存储和计算解决方案的无与伦比的机会。通过利用其获得专利的生物安全DNA和酶促耗材的大规模生产方法，Biomemory能够确保具有竞争力的运营成本（OpEx）。

Its modular IT-friendly architecture and ISO-like qualification protocol can rapidly adapt to the acquired technology, software and equipment, providing a significant time-to-market pull and capex-efficient solutions for customers..

其模块化的 IT 友好架构和类似 ISO 的认证协议能够快速适应所获得的技术、软件和设备，为客户提供显著的上市时间优势和资本支出高效的解决方案。

The Biomemory DNA Card

生物记忆DNA卡

, a proprietary storage container, provides reliable data retention for 50, 100 or 150 years with IT-compatible Uncorrectable Error Rate (UBER) and a unique way of assuring the life-time readability. Leveraging this with the former Catalog solutions will rapidly yield new commercial-grade data storage or cybersecurity solutions. .

，一种专有的存储容器，可提供50年、100年或150年的可靠数据保存时间，具备与IT兼容的不可纠正错误率（UBER），并以独特的方式确保数据在其生命周期内的可读性。将其与之前的目录解决方案结合使用，将迅速产生新的商业级数据存储或网络安全解决方案。

The deep and foundational patent portfolio acquired from Catalog also gives Biomemory the opportunity to add compelling industry-leading search and computing capabilities. Significant speed, cost and robustness can be gained from combining the advanced algorithms from both companies. Multi-layer, 3D printing solutions from Biomemory, together with the large-scale high-throughput printing from Catalog,  will accelerate the massive densification and miniaturization required to match the data center form factor standards for rackable storage servers.                          .

从Catalog收购的深厚且基础性的专利组合，还为Biomemory提供了增加引人注目的行业领先搜索和计算能力的机会。通过结合两家公司的先进算法，可以显著提升速度、降低成本并增强稳健性。Biomemory的多层3D打印解决方案与Catalog的大规模高通量打印技术相结合，将加速实现数据中心机架式存储服务器所需的大规模致密化和小型化。

Both platforms uniquely leverage the mapping of data to biosafe DNA blocks, eschewing base-by-base DNA synthesis. This provides a path toward massive improvement in reading metrics (cost, speed and data volume), and the ability to add a variety of search and computing features inaccessible to bit-to-base encoding schemes, while assuring the strongest 'biosecurity by design.'   .

这两个平台都独特地利用了将数据映射到生物安全的DNA块的方法，避免了逐个碱基的DNA合成。这为读取指标（成本、速度和数据量）提供了大幅提升的途径，同时能够添加位到碱基编码方案无法实现的各种搜索和计算功能，并确保“设计上的最强生物安全性”。

R&D and Production Hub in Boston

波士顿的研发与生产中心

To fully leverage this acquisition, Biomemory has established a flagship office in Boston, housing both a cutting-edge Research & Development laboratory, dedicated Production Units and technical customer support. This hub is integrated within the global Biomemory organization, staffed with key experts from Catalog Technologies, and serves as Biomemory's North American launch pad to expand and accelerate its US go-to-market strategy..

为了充分利用此次收购，Biomemory 在波士顿设立了旗舰办公室，内设尖端的研发实验室、专用的生产部门和技术客户支持。该中心整合进全球 Biomemory 组织，配备了来自 Catalog Technologies 的关键专家，是 Biomemory 在北美的跳板，用以拓展并加速其在美国的市场推广战略。

Path Toward High-Value Mass Deployment

高价值大规模部署之路

'Biomemory is the first company in the DNA Data Storage industry to have implemented a complete end-to-end industrialized process,' stated

“生物记忆是DNA数据存储行业首家实现完整端到端工业化流程的公司，”声明表示。

Olivier Lauvray, VP of Industrialization at Biomemory

奥利维尔·劳夫雷，Biomemory工业化的副总裁

. 'It spans the digital file or object ingestion to DNA writing and storage with a data retention of 50 to 150 years, and

“它涵盖了从数字文件或对象的摄入到DNA的写入和存储，数据保留期限为50到150年，而且

has the capability to access and read stored digital content all along the retention lifetime.'

有能力在保存期限内访问和读取存储的数字内容。

Biomemory intends to launch the first commercial solutions leveraging the asset acquisition in 2H 2026. The company aims to be the first DNA Data Storage provider to be deployed in data centers, offering a tangible, sustainable and secure alternative to traditional data storage media.

Biomemory 计划在 2026 年下半年推出首个利用资产收购的商业解决方案。该公司旨在成为首家部署在数据中心的 DNA 数据存储提供商，为传统数据存储介质提供一种切实可行、可持续且安全的替代方案。

With this massive IP portfolio, technology modules and expertise now consolidated under one roof, Biomemory holds the highest level of industrial readiness in the sector, uniquely positioned to serve the markets from North America and Europe. Customers can expect an advantageous CapEx as well as competitive OpEx, enabling a pathway to mass-market adoption that no other market player can match..

通过这一庞大的知识产权组合、技术模块和专业知识现在整合到一个屋檐下，Biomemory在该领域拥有最高水平的行业准备度，独特地定位为北美和欧洲市场服务。客户可以期待有利的资本支出（CapEx）以及具有竞争力的运营支出（OpEx），开启一条其他市场参与者无法匹敌的通往大众市场采用的道路。

'This acquisition will allow Biomemory to design more compelling DNA Data Storage commercial solutions, progressively adding search and compute functions,' said

“此次收购将使Biomemory能够设计出更具吸引力的DNA数据存储商业解决方案，并逐步增加搜索和计算功能，”

Erfane Arwani, co-founder & CEO, Biomemory

阿拉尼·阿尔瓦尼，联合创始人兼首席执行官，生物记忆

. 'It is serving our ambition of a mass deployment in the IT and data center environment. One more step toward the global reach of Biomemory and a way to get closer to our North American customer base.'

“它正在服务于我们在IT和数据中心环境中的大规模部署目标。这是Biomemory迈向全球覆盖的又一步，也是接近我们北美客户群的一种方式。”

About Biomemory

关于Biomemory

Biomemory was founded in 2021, leveraging many years of research work in Sorbonne University and CNRS French national labs. It is a leading innovator and market player, at the intersection of biotechnology and information technologies. The company develops IT-friendly Data Storage and cybersecurity solutions, using DNA as the storage media.

生物记忆公司成立于2021年，利用了索邦大学和法国国家科学研究中心（CNRS）多年的研发工作。该公司是生物技术和信息技术交叉领域的领先创新者和市场参与者。公司使用DNA作为存储介质，开发对信息技术友好的数据存储和网络安全解决方案。

Solutions are built and industrialized to ensure data retention and readability up to 150 years. With a commitment to environmental sustainability, Biomemory's technology is offering a path toward cost-effective and energy-efficient mass cold storage. Its ambition is to serve a broad range of customers requiring long-lasting data storage and computing, from Kilo-Bytes to Exa-Bytes..

解决方案的构建和工业化旨在确保数据保留和可读性长达150年。凭借对环境可持续性的承诺，Biomemory的技术提供了一条通往高性价比和节能的大规模冷存储之路。其目标是服务于需要持久数据存储和计算的广泛客户，从千字节到艾字节不等。

Biomemory is headquartered in Paris, France, with an R&D and production center in Boston, USA

生物记忆总部位于法国巴黎，在美国波士顿设有研发和生产中心。

SOURCE Biomemory

源生物记忆

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示